BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 20167814)

  • 1. Expression of synaptic vesicle protein 2A in epilepsy-associated brain tumors and in the peritumoral cortex.
    de Groot M; Toering ST; Boer K; Spliet WG; Heimans JJ; Aronica E; Reijneveld JC
    Neuro Oncol; 2010 Mar; 12(3):265-73. PubMed ID: 20167814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synaptic vesicle protein 2A tumoral expression predicts levetiracetam adverse events.
    Romoli M; Mandarano M; Romozzi M; Eusebi P; Bedetti C; Nardi Cesarini E; Verzina A; Calvello C; Loreti E; Sidoni A; Giovenali P; Calabresi P; Costa C
    J Neurol; 2019 Sep; 266(9):2273-2276. PubMed ID: 31168673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression patterns of synaptic vesicle protein 2A in focal cortical dysplasia and TSC-cortical tubers.
    Toering ST; Boer K; de Groot M; Troost D; Heimans JJ; Spliet WG; van Rijen PC; Jansen FE; Gorter JA; Reijneveld JC; Aronica E
    Epilepsia; 2009 Jun; 50(6):1409-18. PubMed ID: 19220410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of ADK in human astrocytic tumors and peritumoral tissue is related to tumor-associated epilepsy.
    de Groot M; Iyer A; Zurolo E; Anink J; Heimans JJ; Boison D; Reijneveld JC; Aronica E
    Epilepsia; 2012 Jan; 53(1):58-66. PubMed ID: 22092111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synaptic vesicle protein 2A predicts response to levetiracetam in patients with glioma.
    de Groot M; Aronica E; Heimans JJ; Reijneveld JC
    Neurology; 2011 Aug; 77(6):532-9. PubMed ID: 21795655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of brain-derived neurotrophic factor and tyrosine kinase B receptor proteins in glioneuronal tumors from patients with intractable epilepsy: colocalization with N-methyl-D-aspartic acid receptor.
    Aronica E; Leenstra S; Jansen GH; van Veelen CW; Yankaya B; Troost D
    Acta Neuropathol; 2001 Apr; 101(4):383-92. PubMed ID: 11355310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decreased expression of synaptic vesicle protein 2A, the binding site for levetiracetam, during epileptogenesis and chronic epilepsy.
    van Vliet EA; Aronica E; Redeker S; Boer K; Gorter JA
    Epilepsia; 2009 Mar; 50(3):422-33. PubMed ID: 18717715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic Role of Synaptic Vesicle Glycoprotein 2A (SV2A) in Modulating Epileptogenesis.
    Ohno Y; Tokudome K
    CNS Neurol Disord Drug Targets; 2017; 16(4):463-471. PubMed ID: 28393712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of connexin 43 and connexin 32 gap-junction proteins in epilepsy-associated brain tumors and in the perilesional epileptic cortex.
    Aronica E; Gorter JA; Jansen GH; Leenstra S; Yankaya B; Troost D
    Acta Neuropathol; 2001 May; 101(5):449-59. PubMed ID: 11484816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential expression of synaptic vesicle protein 2A after status epilepticus and during epilepsy in a lithium-pilocarpine model.
    Contreras-García IJ; Pichardo-Macías LA; Santana-Gómez CE; Sánchez-Huerta K; Ramírez-Hernández R; Gómez-González B; Rocha L; Mendoza Torreblanca JG
    Epilepsy Behav; 2018 Nov; 88():283-294. PubMed ID: 30336420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Down-regulation synaptic vesicle protein 2A in the anterior temporal neocortex of patients with intractable epilepsy.
    Feng G; Xiao F; Lu Y; Huang Z; Yuan J; Xiao Z; Xi Z; Wang X
    J Mol Neurosci; 2009 Nov; 39(3):354-9. PubMed ID: 19757204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synaptic vesicle protein2A decreases in amygdaloid-kindling pharmcoresistant epileptic rats.
    Shi J; Zhou F; Wang LK; Wu GF
    J Huazhong Univ Sci Technolog Med Sci; 2015 Oct; 35(5):716-722. PubMed ID: 26489628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preferential increase in the hippocampal synaptic vesicle protein 2A (SV2A) by pentylenetetrazole kindling.
    Ohno Y; Ishihara S; Terada R; Kikuta M; Sofue N; Kawai Y; Serikawa T; Sasa M
    Biochem Biophys Res Commun; 2009 Dec; 390(3):415-20. PubMed ID: 19751703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential expression patterns of chloride transporters, Na+-K+-2Cl--cotransporter and K+-Cl--cotransporter, in epilepsy-associated malformations of cortical development.
    Aronica E; Boer K; Redeker S; Spliet WG; van Rijen PC; Troost D; Gorter JA
    Neuroscience; 2007 Mar; 145(1):185-96. PubMed ID: 17207578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of Differential Expression of Synaptic Vesicle Protein 2A in the Adult Rat Brain.
    Mendoza-Torreblanca JG; García-Cruz ME; Sánchez-Cruz I; Gomez-Gonzalez B; Juárez-Méndez S; Gómez-Lira G
    Neuroscience; 2019 Nov; 419():108-120. PubMed ID: 31520710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression and cellular distribution of multidrug transporter proteins in two major causes of medically intractable epilepsy: focal cortical dysplasia and glioneuronal tumors.
    Aronica E; Gorter JA; Jansen GH; van Veelen CW; van Rijen PC; Leenstra S; Ramkema M; Scheffer GL; Scheper RJ; Troost D
    Neuroscience; 2003; 118(2):417-29. PubMed ID: 12699778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam.
    Lynch BA; Lambeng N; Nocka K; Kensel-Hammes P; Bajjalieh SM; Matagne A; Fuks B
    Proc Natl Acad Sci U S A; 2004 Jun; 101(26):9861-6. PubMed ID: 15210974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression and cellular distribution of high- and low-affinity neurotrophin receptors in malformations of cortical development.
    Aronica E; Ozbas-Gerçeker F; Redeker S; Ramkema M; Spliet WG; van Rijen PC; Leenstra S; Gorter JA; Troost D
    Acta Neuropathol; 2004 Nov; 108(5):422-34. PubMed ID: 15375667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Function of synaptic vesicle protein 2A (SV2A) as a novel therapeutic target for epilepsy].
    Tokudome K; Shimizu S; Serikawa T; Ohno Y
    Nihon Yakurigaku Zasshi; 2018; 152(6):275-280. PubMed ID: 30531097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein.
    Gillard M; Chatelain P; Fuks B
    Eur J Pharmacol; 2006 Apr; 536(1-2):102-8. PubMed ID: 16556440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.